Articles tagged with Chemotherapy
The EORTC trial 26951 found that CpG island methylator phenotype status and MGMT promoter methylation are key factors in determining which patients benefit from PCV chemotherapy. The study suggests that other molecularly defined subsets of grade III tumors may also respond to treatment.
A study from Western University has identified the Numb-p53 pathway as a key mechanism underlying chemotherapy resistance in triple-negative breast cancer. By targeting this pathway, researchers hope to develop novel therapies that can sensitize cancer cells to chemotherapy.
Researchers have developed a new drug delivery system that uses nanoparticles and siRNA to target lung cancer cells, eliminating resistance and reducing systemic damage. In laboratory tests, the system showed significant improvement in treating lung tumors, with nearly 83% of the drug delivered directly to the lungs.
A University of Michigan Health System study found that peripherally inserted central catheters more than double the risk of blood clots in critically ill patients and those with cancer. The device is often used for IV medication delivery and has lower infection risks, but may not be suitable for all patients.
Cancer chemotherapy can cause peripheral neuropathy and delay recovery after bone marrow transplantation. Researchers at Albert Einstein College of Medicine discovered that nerve damage in the bone marrow also causes anemia by impairing hematopoietic stem cell regeneration.
Researchers at The Jackson Laboratory identified a molecule that prevents repair of some cancer cells, providing a potential new approach to cancer treatment. The molecule, DIDS, blocks the DNA repair action in chronic lymphocytic leukemia (CLL), causing cancer cells to die while leaving healthy cells unaffected.
A new study identifies osteopontin as a potential new leukemia treatment target. The protein helps leukemia cells avoid the effects of chemotherapy by appearing dormant in the bone marrow environment.
Researchers identified an eight-gene signature that correlates with chemotherapy outcome in lung and breast cancer patients. The gene signature, which includes the receptor for growth factor EGF, helps predict relapse-free survival after chemotherapy.
Gabriel Hortobagyi, a renowned breast cancer researcher, is being recognized for his contributions to advancing minority investigators in cancer research. He has developed groundbreaking therapies and treatment regimens that have become standard practices for managing breast cancer.
A Mayo Clinic study found gene variations that can predict chemotherapy-induced peripheral neuropathy, a debilitating condition affecting 20-30% of cancer patients. The study implicates genes EPHA5, ARHGEF10, and PRX, enabling clinicians to individualize treatment and improve patient outcomes.
Researchers at Penn Medicine discovered that cells with low helicase-like transcription factor (HLTF) expression are more likely to respond to autophagy inhibition. This finding could lead to the development of a predictive biomarker for patients who may benefit from this treatment approach.
A Phase III clinical trial found that adding cetuximab to chemotherapy enables previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis. The combination also extends median overall survival by 10 months compared to chemotherapy alone.
Researchers found that Paragazole increases the sensitivity of triple-negative breast cancer cells to chemotherapy by inducing expression of estrogen receptors. The drug outperforms chemotherapy alone in a range of breast cancer cell lines, offering new hope for treatment options.
New research reveals chemotherapy activates the body's immune system to target and destroy cancer cells. The treatment converts dying tumors into therapeutic vaccines, boosting the host's immune response against cancer.
A randomized phase 3 trial found that duloxetine reduced pain from chemotherapy-induced peripheral neuropathy compared to placebo. Patients who received platinums showed greater benefits from duloxetine.
Scientists investigate multidrug transporters and anionic lipids to improve antibiotic, anti-malarial, and cancer treatment effectiveness. By understanding lipid-protein interactions, they aim to develop novel drugs that can control these protein complexes.
A new chemotherapy drug, arsenic trioxide, has been developed to be less toxic to female fertility while being more effective against cancer. The drug is packed into a nanobin, a tiny Trojan horse that delivers the drug directly to tumor cells.
EPFL scientists have developed a tiny implant that can analyze proteins and organic acids in the blood, sending results to doctors' computers for more personalized care. The device has demonstrated reliable detection of several substances and has potential applications in chemotherapy and chronic illness monitoring.
A study found that medicines intended for chronic use lack sufficient patients to evaluate safety and efficacy. The number of patients studied before regulatory approval was often lower than recommended guidelines specify.
A UK study found that epigenetic changes play a key role in the development of chemotherapy resistance in bladder cancer. The researchers identified DNA hypermethylation as a potential biomarker to predict response to treatment, which could increase pathological complete response rates and spare nonresponders from adverse events.
Researchers are developing tiny sensory implants that can measure vital tumor factors, enabling doctors to target radiotherapy and chemotherapy for more effective treatment. The devices aim to personalize therapy based on individual patient responses, improving recovery chances.
Researchers have found that inhibiting the Mer receptor increases sensitivity to chemotherapy in leukemia cells, reducing toxic side effects while maintaining effectiveness.
Researchers found African-Americans have a 1.4-fold greater risk for heart failure compared to their white counterparts after breast cancer treatment. The study also highlights the importance of closer monitoring and pretreatment with cardioprotective drugs.
A clinical trial comparing two treatments for advanced head and neck cancer found that adding a targeted biologic therapy to chemotherapy did not improve patient outcomes. The study's results suggest that the current standard of care therapy may be sufficient, at least for now.
A prospective study found that children with low-risk retinoblastoma do not need postoperative chemotherapy to prevent disease recurrence or metastasis. The results suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment or even forego it altogether.
A new tool developed by EPFL researchers can accurately determine the optimal dose of chemotherapy for individual patients, reducing the risk of resistance mechanisms and relapse. The method measures a cancerous cell's electrical conductivity to assess the treatment's effect, allowing oncologists to make more patient-specific decisions.
Bioengineering researchers at UC Santa Barbara found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more effective at targeting and delivering anti-cancer drugs to breast cancer cells. The rod-shaped nanoparticles were engineered with an antibody called trastuzumab t...
Researchers at the University of Minnesota have identified a genetic variation in CD33 that significantly affects the clinical outcome of AML patients who received gemtuzumab ozogamicin chemotherapy. This discovery may help predict which patients are most likely to benefit from the treatment and improve therapeutic efficacy.
Scientists found that distinct niches exist in bone marrow to nurture different types of blood stem cells, which could improve the success of stem cell transplants and chemotherapy. The discovery suggests that targeting specific support cells may be therapeutic for treating certain cancers.
A study by Rutgers University behavioral neuroscientist Tracey Shors found that prolonged chemotherapy decreases the development of new brain cells, disrupting ongoing brain rhythms necessary for learning. This can lead to cognitive problems such as short-term memory loss and disordered thinking in cancer patients.
A study published in Blood found that certain chemotherapies increase a patient's risk of developing therapy-related acute myeloid leukemia (tAML), a rare but frequently fatal condition. The risk varies by type of cancer and year of diagnosis, with some patients facing higher risks more than 10 years after their initial diagnosis.
Researchers at Johns Hopkins Kimmel Cancer Center create cell lines from patients' own tumors to predict chemotherapy sensitivity. The new method may replace current laboratory tests and improve drug selection accuracy.
Researchers evaluated CT scans of patients with localized esophageal cancer before and after chemotherapy to identify changes in tumor texture. Smaller change in skewness following chemotherapy was a significant prognostic factor, with median overall survival increasing from 11.1 months to 36.1 months.
A study published in the Journal of Clinical Investigation found that TGF-β is highly expressed in triple negative breast cancer cells after chemotherapy. In a mouse model, blocking TGF-β prevented tumor recurrence and enhanced chemotherapy action against triple negative breast cancer.
A pair of commentaries highlight a public health debate surrounding CDC treatment guidelines for exposed individuals during the 2012 fungal meningitis outbreak. The American Society for Microbiology has published two commentaries questioning and defending the CDC's recommendations.
A phase 1 clinical trial found that high-dose Vorinostat, combined with standard chemotherapy, was effective in treating relapsed lymphomas, particularly Hodgkin and diffuse large B-cell lymphomas. The study resulted in a 70% response rate, including complete responses in some patients.
Researchers discover gene FBH1 crucial for chemotherapy's effectiveness in killing cancer cells. By understanding the role of FBH1, doctors can tailor treatment to individual patients based on genetic fingerprint.
A new study led by Robert G. Hawley may help predict which patients with multiple myeloma will respond better to certain treatments. The researchers discovered a test that can detect tumor-propagating cells, which are responsible for disease relapse.
A new drug called calmangafodipir has been developed to protect healthy cells from side effects of cancer treatments while enhancing the anti-tumor effect. The compound was derived from a contrast media used in magnetic resonance scans and shows promise in reducing white blood cell counts and preventing infections.
Scientists at UC Santa Cruz used a novel technique to study the structural and mechanical properties of telomeres, which could guide the development of new anti-cancer drugs. The research found that a small structural displacement causes the G-quadruplex structure to unfold, revealing its mechanical stability.
A Michigan State University study found that many cancer patients struggle to follow complex chemo prescriptions, leading to poor adherence and reduced treatment efficacy. The researchers suggest an automated calling system could help patients take their drugs properly.
Researchers at Johns Hopkins Medicine developed a method to track liver tumors' response to chemotherapy using paired CT scans, allowing for immediate feedback on treatment effectiveness. This technique has the potential to save patients from delayed diagnosis and reduced treatment efficacy.
A large study finds that post-menopausal breast cancer survivors are more likely to develop diabetes, with a significant association observed after chemotherapy. The risk increases over time, suggesting the need for closer monitoring and screening of these patients.
A clinical trial at Dana-Farber Cancer Institute found that intensified chemotherapy significantly reduces relapse odds for young patients with B-precursor acute lymphoblastic leukemia (B-ALL). The treatment regimen improved event-free survival rates to 76% five years after complete remission.
Researchers at UCLA's Jonsson Comprehensive Center have identified liposarcoma tumors that can be imaged by PET scanning using a tracer substance known as FAC, and found these tumors are sensitive to chemotherapy. This discovery has translational potential for liposarcoma patients and may lead to more effective treatment strategies.
Researchers develop experimental small molecule agent MI-2 that irreversibly inactivates MALT1 protein responsible for cancer cell growth. The treatment shows promise in animal models without toxicity, paving the way for combination therapy regimens to reduce treatment toxicity and improve patient outcomes.
A University of Rhode Island researcher has discovered that orlistat strongly alters the therapeutic potential of anti-cancer drugs and blood thinners like aspirin. The drug's inhibition of a key enzyme can lead to severe toxicity in internal organs such as the liver and kidney.
A Phase II clinical trial found that over a third of high-risk leukemia patients responded to the experimental new drug quizartinib, experiencing complete remission and potentially life-saving bone marrow transplants. Many participants who did well with the drug had failed to respond to prior therapies.
Researchers found that a specific genetic marker, WT1 SNP rs16754, is correlated with improved outcomes and reduced treatment-related mortality in pediatric patients with AML. The study suggests personalized cancer treatment may improve survival and reduce toxicity by considering individual genetic makeup.
The Deshpande Center has awarded grants to ten MIT research teams working on early-stage technologies with the potential to significantly impact various fields. These projects aim to develop new technological innovations in areas such as cancer treatment, computation, and food production.
A clinical trial testing this hypothesis should begin soon, combining chemotherapy agents with a new approach to target the immune system. The study found that blocking negative immune system activation increases the efficiency of chemotherapy.
Research by Nemours and University of Delaware teams found improved quality of life and survival in leukemia patients treated with nanoparticle-based drug delivery. The approach reduces side effects and allows precise targeting of cancer cells, offering a promising alternative to traditional chemotherapy.
Researchers have found that dual-agent chemotherapy resistance in ovarian cancer arises from unique genetic changes, distinct from single-agent resistance. This discovery may lead to new strategies for overcoming resistance and improving treatment outcomes.
A new study demonstrates that a targeted therapy, selumetinib, and chemotherapy work better together than chemotherapy alone in treating patients with KRAS-mutant non-small cell lung cancer. The combination improved patient survival by 3.2 months and showed significant tumor shrinkage, offering hope for a potential new treatment strategy.
A study using PET/CT imaging found statistically significant decreases in regional brain metabolism associated with symptoms of chemo brain phenomenon. Researchers hope to establish a prospective study to improve treatment for patients experiencing this debilitating condition.
Researchers at the University of New South Wales have developed a non-toxic nanoparticle that can deliver nitric oxide to specific cancer cells, reducing chemotherapy doses by a factor of five. This could lead to improved treatment outcomes and reduced side effects for neuroblastoma patients.
Researchers found that certain 'checkpoint mutants' ignore the normal signal to stop replicating DNA after losing nucleotides, instead continuing to unwind and create damaged DNA strands.
A new study found that adding Gemtuzumab Ozogamicin to chemotherapy treatment improved the effectiveness of cancer treatment without increasing side effects in older AML patients. The results show a 22% lower risk of relapse and a 13% lower mortality rate compared to standard treatment.
A promising stem-cell-based approach has been successfully demonstrated in non-human primates, where transplanted spermatogonial stem cells produce functional sperm. Cancer patients who undergo chemotherapy often become infertile due to treatment damage, but preserving and transplanting SSCs may restore fertility.
Researchers at Brigham and Women's Hospital have developed a first-of-its-kind self-assembled nanoparticle that can deliver chemotherapy specifically to cancer cells and release it in response to external NIR light, creating heat for synergistic anti-tumor efficacy. The platform successfully eradicated tumors in pre-clinical models.